Variables | Hyperthyroidism | Subclinical hyperthyroidism | P value |
---|---|---|---|
Number | 90 | 88 | n/a |
Mean age (years) | 41.0 + 13.5 | 45.1 + 15.6 | 0.060 |
Female (%) | 73.3 | 75 | 0.467 |
Presenting symptoms | |||
Dysphagia and/or hoarseness (%) | 2.2 | 5.7 | 0.213 |
Neck swelling (%) | 7.8 | 4.6 | 0.281 |
Neck tenderness (%) | 4.4 | 0.0 | 0.063 |
Weight loss (%) | 13.3 | 3.4 | 0.016 |
Tremor (%) | 11.1 | 3.4 | 0.044 |
Palpitation (%) | 14.4 | 2.3 | 0.003 |
Fatigue (%) | 8.9 | 2.3 | 0.054 |
Anxiety (%) | 3.3 | 3.4 | 0.648 |
Insomnia (%) | 2.2 | 0.0 | 0.254 |
Headache (%) | 3.3 | 2.3 | 0.511 |
Nausea and/or vomiting (%) | 1.1 | 1.1 | 0.746 |
Eye manifestations (%) | 14.4 | 12.5 | 0.437 |
Heat intolerance (%) | 2.2 | 2.3 | 0.681 |
Comorbidities | |||
Upper respiratory tract infection (%) | 13.3 | 13.6 | 0.563 |
Hypertension (%) | 12.2 | 19.3 | 0.137 |
Hyperlipidemia (%) | 11.1 | 9.1 | 0.422 |
Type II Diabetes (%) | 14.4 | 26.1 | 0.039 |
Type I diabetes (%) | 2.2 | 1.1 | 0.508 |
Anemia (%) | 5.6 | 12.5 | 0.087 |
Dermatitis (%) | 15.6 | 14.8 | 0.525 |
Ischemic heart disease (%) | 0.0 | 2.3 | 0.243 |
Stroke (%) | 0.0 | 2.3 | 0.243 |
Deep vein thrombosis and/or pulmonary embolism (%) | 2.2 | 1.1 | 0.508 |
Medications | |||
Carbimazole usage prior to the thyroid scan (%) | 20.5 | 30.7 | 0.071 |
Carbimazole usage after the thyroid scan (%) | 14.4 | 10.2 | 0.266 |
Carbimazole usage during the thyroid scan (%) | 35.6 | 17.1 | 0.004 |
Propranolol (%) | 41.1 | 22.7 | 0.007 |
Amiodarone (%) | 0.0 | 1.1 | 0.494 |
Artificial eye tears (%) | 6.7 | 4.6 | 0.388 |
Laboratory data | |||
TSH (milli-international units per liter) | 0.019 + 0.04 | 0.083 + 0.10 | < 0.001 |
Free T4 (pmol/L) | 28.7 + 9.9 | 14.5 + 2.4 | < 0.001 |
Free T3 (pmol/L) | 15.0 + 10.7 | 5.2 + 1.2 | < 0.001 |
Antithyroid peroxidase antibody (IU/mL) | 137.2 + 228.9 | 736.2 + 1495.5 | 0.309 |
Antithyroglobulin antibody (IU/mL) | 140.6 + 185.1 | 384.7 + 657.8 | 0.161 |
Vitamin D (ng/mL) | 23.4 + 10.4 | 22.4 + 9.0 | 0.289 |
Erythrocyte sedimentation rate (ESR) (mm/hr) | 34.5 + 24.3 | 34.4 + 24.7 | 0.995 |
C-Reactive protein (CRP) (mg/L) | 9.8 + 12.4 | 11.3 + 9.3 | 0.719 |
Thyroid ultrasound | |||
Enlarged thyroid gland (%) | 25.0 | 31.1 | 0.605 |
Heterogenous (%) | 52.2 | 61.4 | 0.337 |
Hypervascular (%) | 38.9 | 31.8 | 0.392 |
Bilateral lymph node enlargement (%) | 22.2 | 33.0 | 0.404 |
Unilateral lymph node enlargement (%) | 2.2 | 1.1 | |
Multiple lymph node enlargement (%) | 27.8 | 38.6 | 0.093 |
Single lymph node enlargement (%) | 10.0 | 15.9 | |
Thyroid uptake and scan | |||
Heterogenous (%) | 26.7 | 48.9 | 0.006 0.006 |
Homogenous (%) | 66.7 | 43.2 | |
Mean uptake (%) | 17.6 + 9.5 | 13.2 + 3.8 | 0.373 |
Graves’ disease (%) | 40 | 13.6 | 0.002 |
Thyroiditis (%) | 8.9 | 27.3 | |
Normal (%) | 2.2 | 5.7 | |
Autonomous nodule (%) | 6.7 | 3.4 | |
Toxic multi-nodular goiter (%) | 34.4 | 40.9 | |
Simple goiter (%) | 4.4 | 4.5 | |
Nodular goiter with cold nodule (%) | 0.0 | 2.2 | |
Cold nodule (%) | 1.1 | 1.1 | |
Toxic multi-nodular goiter with a cold nodule (%) | 1.1 | 1.1 | |
Marine-Lenhart syndrome (%) | 2.2 | 0.0 | |
Normal scan while taking carbimazole (%) | 17.8 | 11.4 | 0.159 |